Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Elbein, S. C.
Right arrow Articles by Karim, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Elbein, S. C.
Right arrow Articles by Karim, M. A.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Diabetes Care 27:1968-1973, 2004
© 2004 by the American Diabetes Association, Inc.


Pathophysiology/Complications
Original Article

Does the Aspartic Acid to Asparagine Substitution at Position 76 in the Pancreas Duodenum Homeobox Gene (PDX1) Cause Late-Onset Type 2 Diabetes?

Steven C. Elbein, MD1,2 and Mohammad A. Karim, MD, PHD2

1 Central Arkansas Veterans Healthcare System, Little Rock, Arkansas
2 University of Arkansas for Medical Sciences, Little Rock, Arkansas

Address correspondence and reprint requests to Steven C. Elbein, MD, Professor of Medicine, University of Arkansas for Medical Sciences, Endocrinology 111J-1/LR, JLM VA Hospital, 4300 West 7th St., Little Rock, AR 72205. E-mail: elbeinstevenc{at}uams.edu

OBJECTIVE—Considerable data support an inherited defect in insulin secretion as one component of type 2 diabetes. Coding variants of the pancreas duodenum homeobox gene (PDX1) were proposed to predispose late-onset type 2 diabetes and to decrease transactivation in vitro. We tested the hypothesis that the Asp76Asn (D76N) variant that was identified in several populations predisposed type 2 diabetes and reduced insulin secretion.

RESEARCH DESIGN AND METHODS—We performed a case-control study in 191 control subjects and 190 individuals with type 2 diabetes, all of European descent, then characterized the D76N variant in 704 members of 68 families. We compared the phenotypic characteristics of those with and without the variant by diagnostic status and determined the insulin secretory response to intravenous glucose and tolbutamide among nondiabetic family members.

RESULTS—D76N was not associated with type 2 diabetes, either in our population or when all reported studies in Caucasians were combined. D76N did not segregate with diabetes among the families examined. Among D76N carriers, nondiabetic individuals had a lower waist-to-hip ratio and a trend to lower BMI than their diabetic counterparts. Diabetic carriers of D76N were significantly leaner by BMI (P = 0.012) and tended to be younger than diabetic individuals with the D/D genotype. However, insulin secretion in response to oral and intravenous glucose challenge and to intravenous tolbutamide was not reduced in D76N carriers.

CONCLUSIONS—The D76N variant of PDX1 does not significantly alter insulin secretion or act as a high-risk susceptibility allele for late-onset type 2 diabetes as proposed previously, although we cannot exclude a minor role in increasing risk of diabetes.

Abbreviations: AIRg, acute insulin response to glucose • FSIGT, frequently sampled intravenous glucose tolerance test • IGT, impaired glucose tolerance


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
K. Eto, V. Kaur, and M. K. Thomas
Regulation of Pancreas Duodenum Homeobox-1 Expression by Early Growth Response-1
J. Biol. Chem., March 2, 2007; 282(9): 5973 - 5983.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
S. C. Elbein, X. Wang, M. A. Karim, B. I. Freedman, D. W. Bowden, A. R. Shuldiner, F. L. Brancati, and W. H. L. Kao
Role of a Proline Insertion in the Insulin Promoter Factor 1 (IPF1) Gene in African Americans With Type 2 Diabetes.
Diabetes, October 1, 2006; 55(10): 2909 - 2914.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M.-J. Boucher, L. Selander, L. Carlsson, and H. Edlund
Phosphorylation Marks IPF1/PDX1 Protein for Degradation by Glycogen Synthase Kinase 3-dependent Mechanisms
J. Biol. Chem., March 10, 2006; 281(10): 6395 - 6403.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2004 by the American Diabetes Association.